Zevra Therapeutics (ZVRA) News Today $10.31 +0.25 (+2.49%) Closing price 04:00 PM EasternExtended Trading$10.06 -0.25 (-2.42%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Zevra Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Zevra Therapeutics (ZVRA) Expected to Post Earnings on TuesdayOctober 27 at 9:10 AM | marketbeat.comAnalyzing Indivior (NASDAQ:INDV) & Zevra Therapeutics (NASDAQ:ZVRA)October 24, 2026 | americanbankingnews.comZevra Therapeutics Announces Details for Q3 2026 Financial Results CallOctober 20, 2026 | globenewswire.comZevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's DealOctober 15, 2026 | seekingalpha.comZevra Therapeutics (NASDAQ:ZVRA) Stock: Insider Neil Mcfarlane Sells 20,000 SharesOctober 14, 2026 | insidertrades.comInsider Selling: Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells $225,000.00 in StockOctober 13, 2026 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Falls 5.1% - Here's WhyOctober 13, 2026 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Consensus Price Target of $27.14October 8, 2026 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Jumps 4.6% - Here's WhyOctober 7, 2026 | marketbeat.comZevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing FactorOctober 6, 2026 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comZevra Therapeutics to Present at Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comZevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual SymposiumAugust 25, 2026 | quiverquant.comQZevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumAugust 25, 2026 | globenewswire.comRoth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)August 23, 2026 | theglobeandmail.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAAugust 13, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAAugust 11, 2026 | globenewswire.comWhat Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?August 7, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAAugust 6, 2026 | prnewswire.comZevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041August 6, 2026 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call TranscriptAugust 5, 2026 | seekingalpha.comZevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS BeatAugust 5, 2026 | quiverquant.comQZevra Reports Second Quarter 2026 Financial Results and Corporate UpdateAugust 5, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAAugust 4, 2026 | globenewswire.comZevra Therapeutics to Present at the Canaccord Genuity Annual Growth ConferenceAugust 4, 2026 | globenewswire.comZevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & KorsinskyAugust 3, 2026 | prnewswire.comZevra Therapeutics Announces Publication of 4-Year Real-World Data on MIPLYFFA in Niemann-Pick Disease Type CAugust 3, 2026 | quiverquant.comQZevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)August 3, 2026 | globenewswire.comLevi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Zevra Therapeutics (ZVRA)July 30, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAJuly 30, 2026 | prnewswire.comZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)July 29, 2026 | businesswire.comZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS LawJuly 27, 2026 | businesswire.comZevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)July 27, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Roche Holding AG (OtherRHHVF) and Quest Diagnostics (DGX)July 26, 2026 | theglobeandmail.comZevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing ApplicationJuly 24, 2026 | finance.yahoo.comZVRA stock sinks 23% on EU setback — analyst says risk is 'a headwind, but not insurmountable'July 24, 2026 | msn.comZevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type CJuly 24, 2026 | benzinga.comZVRA stock plummets pre-market, heads for worst day in over 5 years – what’s driving the sell-off?July 24, 2026 | msn.comZevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionJuly 24, 2026 | globenewswire.comZevra Therapeutics: Worthy Of An Initial HoldingJuly 23, 2026 | seekingalpha.comZevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference CallJuly 22, 2026 | quiverquant.comQZevra Therapeutics Announces Details for Q2 2026 Financial Results CallJuly 22, 2026 | globenewswire.comZevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)June 23, 2026 | globenewswire.comZevra Therapeutics: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | finanznachrichten.deZevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | markets.businessinsider.comZevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | globenewswire.comIs Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?June 9, 2026 | finance.yahoo.comZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?June 9, 2026 | finance.yahoo.comZevra Therapeutics extends MIPLYFFA exclusivity to 2041June 8, 2026 | finance.yahoo.com Zevra Therapeutics Media Mentions By Week Zevra Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼0.460.69▲Average Healthcare News Sentiment Zevra Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼34▲ZVRA Articles Average Week Zevra Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views1,733-21% Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Supernus Pharmaceuticals News MBX Biosciences News Bausch Health Cos News Prestige Consumer Healthcare News Perrigo News Trulieve Cannabis News Harmony Biosciences News Xeris Biopharma News Mineralys Therapeutics News Trevi Therapeutics News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Zevra Therapeutics dated 10/27/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump Goes "All-In" on Grand Canyon Energy BreakthroughOn July 4th, Washington cut tax credits for solar, wind, and EVs, but extended eight years of credits to one e...Behind the Markets | SponsoredNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
